Covaxin to Use ViroVax’s Technology: Bharat Biotech’s To Use ViroVax’s Technology
The Indian Biotechnology Company headquartered in Hyderabad developed India’s first indigenous COVID-19 vaccine, COVAXIN, in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV), during the month of July 2020.
In order to boost its Covid-19 vaccine candidate Covaxin’s immune response and enable it to have longer-lasting immunity, the company is set to use ViroVax’s technology, using adjuvant Alhydroxiquim-II. The biotechnology company ViroVax LLC at Kanas, US, has licensed its adjuvant, Alhydroxiquim-II to the company. To produce the vaccine candidate, which is an inactivated vaccine obtained from a SARS-CoV-2 virus strain, the inactivated virus is developed with adjuvant from ViroVax.
Bharat Biotech’s Managing Director and Chairman, Krishna Ella stated in a press release, “To achieve long-term protection against pathogens, there is a crucial requirement for growth and accessibility of adjuvants that elucidate mechanisms of action causing increased antibody responses to vaccine antigens. The global vaccine supply’s sustainability can be also enhanced by adjuvants on account of their antigen-sparing effect.”
Sunil David of ViroVax said, “With the support from the National Institutes of Health, it has been possible for ViroVax to collaborate with Bharat
Biotech, and we are delighted.”Additionally, for the discovery and development of treatment, and for the development of subunit vaccine constructs for the prevention of COVID-19 in efforts to fight aginst the pandemic, ViroVax got supplemental funding. ViroVax has found the potential antiviral therapeutics and is evaluating a subunit vaccine candidate. Currently, it is undergoing the testing procedure to determine its efficacy.
The human trials of Bharat Biotech’s novel coronavirus vaccine candidate took place starting from July 2020 after the vaccine received approval from the Drugs Controller General of India (DGCI) for its Phase I & II Human Clinical Trials.
Source
Covaxin to Use ViroVax’s Technology
